English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

in Patients With Acromegaly: 12-Month Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study M Sheppard,1 M Bronstein,2 P Freda,3 O Serri,4 L De Marinis,5 L Naves,6 L Rozhinskaya,7 K Hermosillo Resendiz,8 M Ruffin,9 K Asubonteng,8 A Colao10 1Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham, UK; 2Neuroendocrine Unit, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, Sao Paulo, Brazil; 3Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York, USA; 4Service of Endocrinology, Centre Hospitalier de l’Universite de Montreal, Notre-Dame Hospital, University of Montreal, Montreal, Canada; 5Section of Endocrinology, Department of Internal Medicine, Universita Cattolica del Sacro Cuore, Rome, Italy; 6Department of Endocrinology, Internal Medicine, University of Brasilia, Brasilia, Brazil; 7Department of Neuroendocrinology and Bone Diseases, Endocrinology Research Centre, Moscow, Russia; 8Clinical Development, Novartis Pharmaceuticals Corporation, Florham Park, New Jersey, USA; 9Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland; 10Dipartimento di Medicina Clinica e Chirurgia, Universita Federico II di Napoli, Naples, Italy

endocrine abstracts

Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study